Literature DB >> 36221038

Rose Bengal inhibits β-amyloid oligomers-induced tau hyperphosphorylation via acting on Akt and CDK5 kinases.

Chen-Ye Mou1,2, Yan-Fei Xie2, Jia-Xin Wei1,3, Qi-Yao Wang2, Jing-Yang Le2, Yong-Jie Bao2, Pan-Pan Zhang2, Yue-Chun Mao2, Xing-Han Huang2, Han-Bo Pan2, C Benjamin Naman3, Lin Liu1, Hong-Ze Liang4, Xiang Wu1, Jia Xu1,2, Wei Cui5,6.   

Abstract

RATIONALE: Tau hyperphosphorylation and aggregation is considered as a main pathological mechanism underlying Alzheimer's disease (AD). Rose Bengal (RB) is a synthetic dye used for disease diagnosis, which was reported to inhibit tau toxicity via inhibiting tau aggregation in Drosophila. However, it was unknown if RB could produce anti-AD effects in rodents.
OBJECTIVES: The research aimed to investigate if and how RB could prevent β-amyloid (Aβ) oligomers-induced tau hyperphosphorylation in rodents. METHODS AND
RESULTS: RB was tested in vitro (0.3-1 μM) and prevented Aβ oligomers-induced tau hyperphosphorylation in PC12 cells. Moreover, RB (10-30 mg/kg, i.p.) effectively attenuated cognitive impairments induced by Aβ oligomers in mice. Western blotting analysis demonstrated that RB significantly increased the expression of pSer473-Akt, pSer9-glycogen synthase kinase-3β (GSK3β) and reduced the expression of cyclin-dependent kinase 5 (CDK5) both in vitro and in vivo. Molecular docking analysis suggested that RB might directly interact with GSK3β and CDK5 by acting on ATP binding sites. Gene Ontology enrichment analysis indicated that RB might act on protein phosphorylation pathways to inhibit tau hyperphosphorylation.
CONCLUSIONS: RB was shown to inhibit tau neurotoxicity at least partially via inhibiting the activity of GSK3β and CDK5, which is a novel neuroprotective mechanism besides the inhibition of tau aggregation. As tau hyperphosphorylation is an important target for AD therapy, this study also provided support for investigating the drug repurposing of RB as an anti-AD drug candidate.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Alzheimer’s disease; CDK5; GSK3β; Rose Bengal; Tau

Mesh:

Substances:

Year:  2022        PMID: 36221038     DOI: 10.1007/s00213-022-06232-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.415


  43 in total

1.  Pα-syn* mitotoxicity is linked to MAPK activation and involves tau phosphorylation and aggregation at the mitochondria.

Authors:  Diego Grassi; Natalia Diaz-Perez; Laura A Volpicelli-Daley; Corinne Ida Lasmézas
Journal:  Neurobiol Dis       Date:  2018-11-22       Impact factor: 5.996

2.  Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine.

Authors:  Muhammad Omar Chohan; Sabiha Khatoon; Inge-Grundke Iqbal; Khalid Iqbal
Journal:  FEBS Lett       Date:  2006-06-19       Impact factor: 4.124

3.  Melatonin ameliorates amyloid beta-induced memory deficits, tau hyperphosphorylation and neurodegeneration via PI3/Akt/GSk3β pathway in the mouse hippocampus.

Authors:  Tahir Ali; Myeong Ok Kim
Journal:  J Pineal Res       Date:  2015-05-12       Impact factor: 13.007

4.  Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation.

Authors:  Luis Aragão Gomes; Valerie Uytterhoeven; Diego Lopez-Sanmartin; Sandra O Tomé; Thomas Tousseyn; Rik Vandenberghe; Mathieu Vandenbulcke; Christine A F von Arnim; Patrik Verstreken; Dietmar Rudolf Thal
Journal:  Acta Neuropathol       Date:  2021-01-11       Impact factor: 17.088

Review 5.  Therapeutic strategies for tauopathies and drug repurposing as a potential approach.

Authors:  Majedul Islam; Fengyun Shen; Deepika Regmi; Deguo Du
Journal:  Biochem Pharmacol       Date:  2022-02-24       Impact factor: 6.100

6.  The combination of acyclovir and dexamethasone protects against Alzheimer's disease-related cognitive impairments in mice.

Authors:  Zhang Hui; Yuan Zhijun; Yan Yushan; Chen Liping; Zhou Yiying; Zhang Difan; Choi Tony Chunglit; Cui Wei
Journal:  Psychopharmacology (Berl)       Date:  2020-03-27       Impact factor: 4.530

Review 7.  Tau-targeting therapies for Alzheimer disease.

Authors:  Erin E Congdon; Einar M Sigurdsson
Journal:  Nat Rev Neurol       Date:  2018-07       Impact factor: 42.937

Review 8.  Synergy between amyloid-β and tau in Alzheimer's disease.

Authors:  Marc Aurel Busche; Bradley T Hyman
Journal:  Nat Neurosci       Date:  2020-08-10       Impact factor: 24.884

9.  Chronic low dose of AM404 ameliorates the cognitive impairment and pathological features in hyperglycemic 3xTg-AD mice.

Authors:  Hei-Jen Huang; Shu-Ling Chen; Hsin-Yu Huang; Ying-Chieh Sun; Guan-Chiun Lee; Guey-Jen Lee-Chen; Hsiu Mei Hsieh-Li; Ming-Tsan Su
Journal:  Psychopharmacology (Berl)       Date:  2018-11-13       Impact factor: 4.530

10.  Photodynamic exposure of Rose-Bengal inhibits Tau aggregation and modulates cytoskeletal network in neuronal cells.

Authors:  Tushar Dubey; Nalini Vijay Gorantla; Kagepura Thammaiah Chandrashekara; Subashchandrabose Chinnathambi
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.